Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

NIH Awards $7.8 Million for Innovative HIV Vaccine Approaches

Published: Wednesday, August 22, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
The grants were awarded under the Innovation for HIV Vaccine Discovery initiative, which is expected to receive up to $34.8 million over the next four years.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

"Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development," said NIAID Director Anthony S. Fauci, M.D. "These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection."

The 14 HIV Vaccine Discovery (IHVD) grant recipient organizations include:

Altravax Inc. (Sunnyvale, Calif.)

• Principal Investigator: Robert Whalen, DSc.
• Project title: Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-1.
• The initial award, supported by grant number 1R01AI10270601, is for $597,816 for fiscal year 2012.

Catholic University of America (Washington, D.C.)
• Principal Investigator: Venigalla Rao, Ph.D.
• Project title: Potent Phage T4-Derived V2 Immunogens as HIV Vaccines.
• The initial award, supported by grant number 1R01AI10272501, is for $413,787 for fiscal year 2012.

Dartmouth College (Hanover, N.H.)
• Principal Investigator: Margaret Ackerman, Ph.D.
• Project title: Applying High-Performance Protein Engineering Tools to HIV Immunogen Design.
• The initial award, supported by grant number 1R01AI10269101, is for $479,437 for fiscal year 2012.
Duke University (Durham, N.C.)
• Principal Investigator: Herman Staats, Ph.D.
• Project title: Mucosal Vaccination to Protect Against HIV-1 Infection at Mucosal Sites.
• The initial award, supported by grant number 1R01AI10274701, is for $492,072 for fiscal year 2012.
Harvard Medical School (Boston)
• Principal Investigator: Amitinder Kaur, M.D.
• Project title: Natural Killer T Cells as Modulators of AIDS Vaccine Efficacy.
• The initial award, supported by grant number 1R01AI10269301, is for $846,896 for fiscal year 2012.
Massachusetts General Hospital (Boston)
• Principal Investigator: Galit Alter, Ph.D.
• Project title: Tuning Fc-Effector Functions of HIV-Specific Antibodies.
• The initial award, supported by grant number 1R01AI10266001, is for $609,875 for fiscal year 2012.
NYU Langone Medical Center (New York City)
• Principal Investigator: Catarina Hioe, Ph.D.
• Project title: Contributions of Anti-V2 Antibodies in Protection Against HIV.
• The initial award, supported by grant number 1R01AI10274001, is for $579,543 for fiscal year 2012.
University of California (Irvine)
• Principal Investigator: Donald Forthal, M.D.
• Project title: The Impact of Antibody and pH on Female-to-Male SIV Infection.
• The initial award, supported by grant number 1R01AI10271501, is for $718,324 for fiscal year 2012.
University of Maryland (Baltimore)
• Principal Investigator: Charles Pauza, Ph.D.
• Project title: Neonatal Fc-Receptor-Targeted Mucosal HIV Vaccine.
• The initial award, supported by grant number 1R01AI10268001, is for $779,175 for fiscal year 2012.
University of Medicine and Dentistry of New Jersey (Newark)
• Principal Investigator: Abraham Pinter, Ph.D.
• Project title: Optimizing Protective Vaccine Targets in the V1/V2 Domain of HIV-1 gp120.
• The initial award, supported by grant number 1R01AI10271801, is for $566,739 for fiscal year 2012.
University of Minnesota (Minneapolis)
• Principal Investigator: Ashley Haase, M.D.
• Project title: Vaccine Design to Concentrate Protective Antibodies at the Mucosal Border.
• The initial award, supported by grant number 1R01AI10262501, is for $843,856 for fiscal year 2012.
University of North Carolina (Chapel Hill)
• Principal Investigator: Nikolay Dokholyan, Ph.D.
• Project title: Immunogen Design to Target Carbohydrate-Occluded Epitopes on the HIV envelope.
• The initial award, supported by grant number 1R01AI10273201, is for $514,331 for fiscal year 2012.
University of Rochester (Rochester, N.Y.)
• Principal Investigator: Mark Dumont, Ph.D.
• Project title: Yeast Genetic Approach to Enhance the Immunogenicity of HIV Envelope Glycoprotein.
• The initial award, supported by grant number 1R01AI10273001, is for $386,250 for fiscal year 2012.
University of Texas at El Paso
• Principal Investigator: June Kan-Mitchell, Ph.D.
• Project title: Effector and Regulatory Activities of HLA-E-restricted HIV-specific CD8 T Cells.
• The initial award, supported by grant number 1R01AI10266301, is for $531,600 for fiscal year 2012.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Wednesday, May 18, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Experimental Ebola Antibody Protects Monkeys
Antibody isolated from Ebola survivor can advance to clinical trials.
Friday, February 26, 2016
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Friday, January 15, 2016
In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos